echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Lizhu, Hesco two major groups into the 2 major heavy injections

    Lizhu, Hesco two major groups into the 2 major heavy injections

    • Last Update: 2020-05-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Injection of vancomycin hydrochloric acid is a glycopeptide antimicrobial drug used to treat staphylococcus staphylococcus (beta-lactam resistance) sensitive to vancomycin, as well as endocarditis caused by staphylococcus, glyphosate, bovine streptococcus or diphtheriaVancomycin hydrochloride was isolated from the soil by Lilly and developed, and was approved by the FDA in 1958 for listing under the name VancocinFigure 1: Sales of vancomycin hydrochloric acid in Chinese public medical institutions terminals 2013-2018 (in units: yuan)(source: rice net China's public medical institutions terminal competition pattern)meters net data show that in 2018 China's urban public hospitals, county-level public hospitals, urban community centers and township health hospitals (referred to as China's public health institutions) end injection of vancomycin sales of 1.702 billion yuan, up 1.64 percent year-on-yearFigure 2: 2018 China's public medical institutions terminal injection with hydrochloric acid vancomycin competition pattern(source: Minet China public medical institutions terminal competition pattern)the current domestic market has 6 enterprises with injection of vancomycin production approval, of which 3 are domestic pharmaceutical companies, including Lizhu Group Lizhu Pharmaceutical Factory, Haizheng Pharmaceutical sand and Zhejiang Pharmaceutical Xinchang Pharmaceutical Factory, 3 for imported pharmaceutical companies, including Lilly, KoreaFrom the 2018 China's public medical institutions terminal injection with hydrochloric acid vancomycin competition pattern, the original research manufacturer Lilly accounted for more than 70% of the market sharecompound amino acid injection (18AA-IX) is a compound preparation consisting of essential amino acids and non-essential amino acids, is currently the only special amino acid infusion of 18 kinds of amino acids, clinically used for acute and chronic renal insufficiency patients with hypoproteinemia, low nutritional status and before and after surgery amino acid supplementcompound amino acid injection (18AA-IX) original research manufacturer for japan's Miso Pharmaceutical Co., Ltd., has not been approved to enter the domestic marketThe domestic market only Guangzhou Green Cross Pharmaceuticals, Liaoning Haicisco two enterprises have the product production batch.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.